Media Statement (EN)

Astellas Pharma Europe further aligns to future product portfolio

Leiden, 2 June 2017 – Astellas, the global pharmaceutical company based in Tokyo (Japan) and with operations in Leiden, yesterday presented to the employees of the company a proposal to align its operating model to drive future development product portfolio activities from two global innovation hubs in Northbrook (US) and Tokyo (Jap.). This approach would translate into an exit of Developmentactivities from Astellas’ Leiden location, consolidating scientific leadership and operational activities in Northbrook and Tokyo. To this purpose and in accordance with article 25 of the Works Council Act, the company has submitted a Request for Advice (RfA) to the Astellas Leiden Works Council for this proposal.

The submission of this RfA marks the start of consultation period, during which the Works Council will consult the company leadership on the proposed measures and then present its advice on a path forward.

The proposed model will – if implemented- drive a sustainable, efficient future-state global site strategy and operating model for Astellas, which re-aligns resources to meet the changing needs of the portfolio in an adaptable manner and increase the company’s ability to continue to improve the health of people around the world through the provision of innovative and reliable pharmaceutical products.

Proposed exit of Development, Drug Discovery Research and Clinical Trial Material Manufacturing from Leiden

The proposed model would require an exit of the Development, Drug Discovery Research (DDR) and Clinical Trial Material (CTM) Manufacturing activities from Leiden and subsequent consolidation of these activities into the Northbrook and Tokyo development hubs of the Astellas Group. The model would also require co-location of leadership and project execution in each development hub. A number of functions will be transitioned from Leiden to Northbrook and Tokyo. The Astellas Leiden operation would continue to function as a regional support site for Regulatory Affairs, Pharmacovigilance, Medical Affairs, Quality Assurance, Supply Chain Management and Project & Product Management – maintaining a large Netherlands presence as well as the production location of Astellas in Meppel.

The proposed model is at this stage still subject to the outcome of the Works Council consultation and advice. Astellas will discuss a social plan with Trade Unions and a delegation of the Works council will be invited to join the negotiations. Astellas is committed to working in close cooperation with the Works Council to ensure a timely, yet thorough consultation process. The company is committed to taking all necessary measures to support employee well-being throughout the process. Astellas remains committed to the location in Leiden as well as the Leiden scientific and academic community. 

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at 

Contacts for inquiries or additional information:

Hill+Knowlton Strategies B.V.
Frédérique Demenint

Machteld Merens

Tel: +31 20 404 470


Terug naar boven